Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + zanubrutinib
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenalidomide + zanubrutinib is a combination therapy being investigated for various B-cell malignancies. Zanubrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor that forms a covalent bond with cysteine 481 in the ATP-binding pocket of BTK, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation. Lenalidomide is an immunomodulatory drug with direct anti-tumor activity and immune-enhancing effects. The combination leverages complementary mechanisms to potentially improve outcomes in lymphoid cancers. Clinical trials are evaluating this combination with or without rituximab (as ZR² regimen) for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and other B-cell malignancies.
- Other names
- ZR²ZR2ZR-2ZR 2
02
Targets
BTK (Bruton tyrosine kinase)CRBN (Cereblon)
Beyond the preview
Go deeper on lenalidomide + zanubrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + zanubrutinib.